 Home > Biochemical Engineering > Polypeptide > Nicotinamide mononucleotide for Sale > β-Nicotinamide Mononucleotid

β-Nicotinamide Mononucleotid buy - large image1

β-Nicotinamide Mononucleotid buy - image1

β-Nicotinamide Mononucleotid buy - image2

β-Nicotinamide Mononucleotid buy - image3

β-Nicotinamide Mononucleotid buy - image4

β-Nicotinamide Mononucleotid

TDS 50 Inquiries

Unit Price: Get Latest Price 

CAS No.:

1094-61-7

Grade:

Food Grade

Content:

Port:

hongkong

Brand:

Packaging:

box

Sample Available:

Yes

Price valid (until):

2025-06-28

Contact Supplier

 Chat Now

Hong Kong Lemite Group Limited

Company Type:

Trader

Location:

Hongkong, China

Payment Terms:

TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Qualification:

Main Products:

Peptides

 Visit Store

Product Details
Seller Information
Inquiry History

Description

Product Detail

Description

Retatrutide (LY3437943)Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy. was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.vApixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.Apixaban, also known as BMS-56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement surgery patients. (3) Treatment of both DVT and PE. (4) To reduce the risk of recurring DVT and PE after initial therapy.

Items	Specifications
Items	Specifications
Product Name	Retatrutide
CAS NO.	2381089-83-2
Appearance	white powder
Storage	Cool Dry Place

ECHEMI Editorial Reference

β-nicotinamide mononucleotide is an intermediate in NAD+ biosynthesis produced from nicotinamide (NAM) and phosphoribosyl pyrophosphate (PRPP) by nicotinamide phosphoribosyl transferase enzyme.
NMN zwitterion is a nicotinamide mononucleotide. It has a role as an Escherichia coli metabolite and a mouse metabolite. It is a conjugate base of a NMN(+). It is a conjugate acid of a NMN(-).|3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN.

Certificates

Basic Info

Product Name:

Nicotinamide mononucleotide

Other Name:

Pyridinium,3-(aminocarbonyl)-1-(5-O-phosphono-β-D-ribofuranosyl)-,inner salt;Pyridinium,3-carbamoyl-1-β-D-ribofuranosyl-,hydroxide,5′-(dihydrogen phosphate),inner salt;Pyridinium,3-(aminocarbonyl)-1-(5-O-phosphono-β-D-ribofuranosyl)-,hydroxide,inner salt;3-Carbamoyl-1-β-D-ribofuranosylpyridinium hydroxide,5′-phosphate,inner salt;Nicotinamide mononucleotide;Nicotinamide ribonucleotide;NMN;Nicotinamide ribotide;β-NMN;Nicotinamide ribonucleoside 5′-phosphate;NMN (mononucleotide);β-D-NMN;27626-81-9;1140909-84-7

CAS No.:

1094-61-7

Molecular Formula:

C11H15N2O8P

InChIKeys:

InChIKey=DAYLJWODMCOQEW-TURQNECASA-N

Molecular Weight:

334.22

Exact Mass:

334.056610

EC Number:

214-136-5

UNII:

2KG6QX4W0V

Categories:

Polypeptide

Characteristics

PSA:

166

XLogP3:

-3.5

Storage Conditions:

2-8°C

Collision Cross Section:

165.2 Å² [M]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|165.2 Å² [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|167.13 Å² [M+H]+ [CCS Type: DT, Method: stepped-field]|166 Å² [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|165.8 Å² [M+H]+

See More Nicotinamide mononucleotide Properties 

Hazard Identification

Classification of the substance or mixture

no data available

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)	no data available
Signal word	no data available
Hazard statement(s)	no data available
Prevention	no data available
Response	no data available
Storage	no data available
Disposal	no data available

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Nicotinamide mononucleotide Safety Data Sheet 

Seller Information

Business Type:
Trader

Main Products:
Peptides

Location:
Room 5003, 5th Floor, Yau Lee Centre, 45 Yuen Yuen Road, Kwun Tong, Hong Kong

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Total Annual Revenue:
Less than $1 million

Total Employees:
5-10

Year of Establishment:
2024

Inquiry History

50 Inquiries

Country	Product	Purchase Quantity	Date Posted
Romania	NMN (beta-Nicotinamide Mononucleotide)	1 KG	Oct 22, 2026
Pakistan	Nicotinamide mononucleotide	1.00 MT	Sep 4, 2026
India	Nicotinamide mononucleotide (NMN)	300.00 KG	Sep 4, 2026
India	Nicotinamide mononucleotide (NMN)	50.00 KG	Aug 26, 2026
Pakistan	Nicotinamide	500.00 KG	Jul 24, 2026
Malaysia	L-Methionine	20.00 MT	Jun 16, 2026
India	Nicotinamide mononucleotide (NMN)	150.00 KG	May 11, 2026
Australia	β-Nicotinamide Mononucleotide	1 KG	Apr 17, 2026
India	Nicotinamide mononucleotide	50 G	Apr 8, 2026
Malaysia	L-Methionine	20.00 MT	Apr 1, 2026
United Kingdom	NMN	20 G	Mar 29, 2026
United States	NMN	100 G	Mar 14, 2026
India	Niacinamide	75.00 KG	Feb 25, 2026
Australia	NMN	1 KG	Feb 21, 2026
Netherlands	Nicotinamide Mononucleotide	1 KG	Feb 6, 2026
India	Nicotinamide mononucleotide (NMN)	1.00 KG	Jan 27, 2026
India	Beta-Nicotinamide Mononucleotide	1 KG	Jan 19, 2026
India	Nicotinamide mononucleotide (NMN)	1.00 KG	Nov 26, 2025
India	Nicotinamide mononucleotide	800.00 KG	Nov 17, 2025
Bangladesh	Butyl Acetate	1.00 KG	Nov 11, 2025

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
β-Nicotinamide Mononucleotide 99% Powder SAA09989Z425373 SAA	Cosmetics Grade/99	$1550-1780/KG FOB	M A M M TRANDING ENTERPRISE	Inquiry
β-Nicotinamide Mononucleotide (NMN) Pure Powder Supplier	Food Grade/99.8	$100-130/UNIT FOB	sinofuturepharma	Inquiry
Bulk Nicotinamide Mononucleotide NMN 1094-61-7	Food Grade/99.5	$62/KG FOB	shenzhen Jayoo Biotech Co., Ltd,	Inquiry
CAS 1094-61-7 NMN/β-Nicotinamide Mononucleotide	25kg/bag/	$10-12/KG FOB	Conier Chem&Pharma Limited	Inquiry
top quality Pure 99% β-Nicotinamide mononucleotide raw powder CAS 1094-61-7 NMN	Pharmaceutical Grade/99	$299-345/KG FOB	Hangzhou Beiputai Biotech CO., LTD	Inquiry

β-Nicotinamide Mononucleotid

Product Details

Seller Information